Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Bioorg Med Chem ; 27(14): 3061-3069, 2019 07 15.
Artigo em Inglês | MEDLINE | ID: mdl-31176565

RESUMO

Arginase performs the first enzymatic step in polyamine biosynthesis in Leishmania and represents a promising target for drug development. Polyamines in Leishmania are involved in trypanothione synthesis, which neutralize the oxidative burst of reactive oxygen species (ROS) and nitric oxide (NO) that are produced by host macrophages to kill the parasite. In an attempt to synthesize arginase inhibitors, six 1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives with different substituents at the 4-position of the phenyl group were synthesized. All compounds were initially tested at 100 µM concentration against Leishmania amazonensis ARG (LaARG), showing inhibitory activity ranging from 36 to 74%. Two compounds, 1 (R=H) and 6 (R=CF3), showed arginase inhibition >70% and IC50 values of 12 µM and 47 µM, respectively. Thus, the kinetics of LaARG inhibition were analyzed for compounds 1 and 6 and revealed that these compounds inhibit the enzyme by an uncompetitive mechanism, showing Kis values, and dissociation constants for ternary complex enzyme-substrate-inhibitor, of 8.5 ±â€¯0.9 µM and 29 ±â€¯5 µM, respectively. Additionally, the molecular docking studies proposed that these two uncompetitive inhibitors interact with different LaARG binding sites, where compound 1 forms more H-bond interactions with the enzyme than compound 6. These compounds showed low activity against L. amazonensis free amastigotes obtained from mice lesions when assayed with as much as 30 µM. The maximum growth inhibition reached was between 20 and 30% after 48 h of incubation. These results suggest that this system can be promising for the design of potential antileishmanial compounds.


Assuntos
Antiprotozoários/uso terapêutico , Leishmania/enzimologia , Pirimidinas/uso terapêutico , Antiprotozoários/farmacologia , Pirimidinas/farmacologia
2.
Chem Biol Drug Des ; 86(5): 969-78, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25845502

RESUMO

Arginase is a glycosomal enzyme in Leishmania that is involved in polyamine and trypanothione biosynthesis. The central role of arginase in Leishmania (Leishmania) amazonensis was demonstrated by the generation of two mutants: one with an arginase lacking the glycosomal addressing signal and one in which the arginase-coding gene was knocked out. Both of these mutants exhibited decreased infectivity. Thus, arginase seems to be a potential drug target for Leishmania treatment. In an attempt to search for arginase inhibitors, 29 derivatives of the [1,2,4]triazolo[1,5-a]pyrimidine system were tested against Leishmania (Leishmania) amazonensis arginase in vitro. The [1,2,4]triazolo[1,5-a]pyrimidine scaffold containing R1  = CF3 exhibited greater activity against the arginase rather than when the substituent R1  = CH3 in the 2-position. The novel compound 2-(5-methyl-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)hydrazinecarbothioamide (30) was the most potent, inhibiting arginase by a non-competitive mechanism, with the Ki and IC50 values for arginase inhibition estimated to be 17 ± 1 µm and 16.5 ± 0.5 µm, respectively. These results can guide the development of new drugs against leishmaniasis based on [1,2,4]triazolo[1,5-a]pyrimidine derivatives targeting the arginase enzyme.


Assuntos
Arginase/antagonistas & inibidores , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Leishmania/enzimologia , Pirimidinas/química , Pirimidinas/farmacologia , Tioureia/análogos & derivados , Antiprotozoários/química , Antiprotozoários/farmacologia , Arginase/metabolismo , Linhagem Celular , Desenho de Fármacos , Humanos , Leishmania/efeitos dos fármacos , Leishmaniose/tratamento farmacológico , Tioureia/química , Tioureia/farmacologia
3.
Int J Parasitol ; 32(6): 727-37, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12062491

RESUMO

The genomic organisation of the gene encoding Leishmania (Leishmania) amazonensis arginase as well as its flanking regions were characterised. The size of the transcribed RNA was determined, allowing us to map the genomic sites signalling for RNA trans-splicing and putative polyadenylation regions. The general organisation was compared with genes encoding other proteins already described in organisms of the Trypanosomatid family. The complete nucleotide sequence of the arginase open reading frame was obtained and the three-dimensional structure of the enzyme was inferred by a computational analysis of the deduced amino acid sequence, based on the established crystal structure described for Rattus norvergicus arginase. The human liver arginase sequence was analysed in the same way and the comparison of the presumed structure of both the Leishmania and human enzymes identified some differences that may be exploited in chemotherapeutic studies.


Assuntos
Arginase/genética , DNA de Protozoário/genética , Leishmania/genética , Sequência de Aminoácidos , Animais , Arginase/química , Sequência de Bases , Northern Blotting , Clonagem Molecular , Sondas de DNA/química , DNA de Protozoário/química , Eletroforese em Gel de Campo Pulsado , Regulação Enzimológica da Expressão Gênica , Genômica , Humanos , Leishmania/enzimologia , Modelos Moleculares , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Conformação Proteica , Ratos , Homologia de Sequência de Aminoácidos
4.
J Ethnopharmacol ; 158 Pt A: 49-57, 2014 Dec 02.
Artigo em Inglês | MEDLINE | ID: mdl-25304199

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: The plant Cecropia pachystachya Trécul has been used in Brazilian folk medicine to treat hypertension, bladder and kidney inflammation and renal diseases. The aim of this study was to evaluate the potential of the aqueous fraction from the ethanolic extract of Cecropia pachystachya (FCP) in the management of hypertension, inflammation and progressive renal disease in rats submitted to 5/6 nephrectomy. MATERIALS AND METHODS: Thirty male Wistar rats submitted to 5/6 nephrectomy (5/6 NE) were untreated (NE) or treated (NE+FCP) with the FCP (0.5g/kg/day). The treatment started 15 days after surgery, and the rats were followed for a period of 60 days. Systolic blood pressure (SBP) and albuminuria were evaluated from 15-60 days after the surgical procedure. Function and estructural renal changes, TGF-ß (transforming growth factor ß), MCP-1 (monocyte chemoattractant protein-1) and nitric oxide (NO) urinary excretion were analyzed. Expression and activity of the renal enzymes arginase (ARG), angiotensin converting enzyme (ACE), and MAP kinase p-JNK expression also were analyzed. RESULTS: The nephrectomized rats developed progressive albuminuria and increased SBP that was less intense in the treated group. There was a reduction in the glomerular filtration rate (GFR) in the nephrectomized rats, which was attenuated by treatment with FCP extract. The treatment with FCP also attenuated the histological changes, reduced the expression and activity of renal arginase, the number of macrophages (ED-1 positive cells) and the p-JNK expression in the renal cortex of the rats submitted to 5/6 NE. The urinary excretion of TGF-ß was less intense in the treated group and was associated with the reduction of the expression and activity of the renal arginase. CONCLUSIONS: These results suggest that the reduction of renal arginase activity, p-JNK and TGF-ß expression can explain the mechanism by which the treatment with C. pachystachya reduced the inflammation and improved renal function. This study presents the potential use of Cecropia pachystachya in the treatment of chronic renal diseases.


Assuntos
Cecropia/química , Inflamação/tratamento farmacológico , Nefropatias/tratamento farmacológico , Extratos Vegetais/farmacologia , Albuminúria/tratamento farmacológico , Animais , Arginase/metabolismo , Brasil , Progressão da Doença , Taxa de Filtração Glomerular/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Proteínas Quinases JNK Ativadas por Mitógeno/genética , Rim/efeitos dos fármacos , Rim/enzimologia , Rim/fisiopatologia , Nefropatias/enzimologia , Masculino , Medicina Tradicional , Nefrectomia , Ratos , Ratos Wistar , Fator de Crescimento Transformador beta/genética
5.
J Renin Angiotensin Aldosterone Syst ; 15(4): 430-9, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25002134

RESUMO

INTRODUCTION: Cecropia pachystachya (CP) is a plant rich in polyphenols which inhibits the angiotensin-converting enzyme (ACE) in vitro. Angiotensin II (AII) has an important role in the renal lesion provoked by 5/6 nephrectomy (NE). This study evaluated the CP extract effect on renal lesions provoked by 5/6 NE. MATERIALS AND METHODS: Male Wistar rats submitted to 5/6 NE were treated or not treated with CP extract and followed for 90 days. Systemic blood pressure (SBP), albuminuria, renal functional and structural parameters, ACE activity, urinary levels of monocyte chemoattrant protein-1 (MCP-1) and transforming growth factor ß (TGF-ß) were evaluated. RESULTS: Albuminuria and hypertension were less intense in the treated (NE+CP) group compared to the untreated (NE) group. CP extract treatment reduced the fall in glomerular filtration rate observed in NE rats. Glomerulosclerosis, tubulointerstitial lesions, increase of macrophages and AII positive cells in the renal cortex, as well as increases in renal ACE activity, urinary levels of MCP-1 and TGF-ß were attenuated in NE rats by CP treatment. CONCLUSIONS: The treatment with CP extract reduced the SBP and functional and structural renal changes in 5/6 NE rats. These effects were associated with decreased AII expression, ACE activity and inflammation in the renal cortex.


Assuntos
Cecropia/química , Rim/patologia , Rim/cirurgia , Nefrectomia , Extratos Vegetais/farmacologia , Albuminúria/patologia , Albuminúria/urina , Animais , Pressão Sanguínea/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Brasil , Quimiocina CCL2/urina , Imuno-Histoquímica , Rim/efeitos dos fármacos , Rim/fisiopatologia , Testes de Função Renal , Masculino , Concentração Osmolar , Ratos Wistar , Sístole/efeitos dos fármacos , Fator de Crescimento Transformador beta/urina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA